Pomalidomide (CC4047 or actimid)
This product is for research use only, not for human use. We do not sell to patients.
For small sizes, please check our retail website as below: www.invivochem.com
| Size | Price | Stock |
|---|---|---|
| 1g | $150 | Check With Us |
| 2g | $280 | Check With Us |
| 5g | $470 | Check With Us |
: Cat #: V0035 CAS #: 19171-19-8 Purity ≥ 98%
Description: Pomalidomide (formerly also known as CC-4047 or actimid), an analog of thalidomide, is a potent and orally bioavailable immunomodulatory molecule with antineoplastic activity.
Top Publications Citing Invivochem Products
Publications Citing InvivoChem Products
Product Promise
- Physicochemical and Storage Information
- Protocol
- Related Biological Data
- Stock Solution Preparation
- Quality Control Documentation
| Molecular Weight (MW) | 273.24 |
|---|---|
| Molecular Formula | C13H11N3O4 |
| CAS No. | 19171-19-8 |
| Storage | -20℃ for 3 years in powder formr |
| -80℃ for 2 years in solvent | |
| Solubility In Vitro | DMSO: 55 mg/mL (201.28 mM) )r |
| Water:<1 mg/mL (slightly soluble or insoluble)r | |
| Ethanol: <1 mg/mL | |
| Solubility In Vivo | 1% DMSO+30% polyethylene glycol+1% Tween 80: 15 mg/mL |
| SMILES Code | O=C1N(C(CC2)C(NC2=O)=O)C(C3=C1C=CC=C3N)=O |
| Synonyms | Pomalidomide; CC4047; CC 4047; CC-4047; Brand name: Pomalyst. |
| Protocol | In Vitro | Pomalidomide also inhibits Whole Blood TNF-α with IC50 of 25 nM. |
|---|---|---|
| In Vivo | The administration of Pomalidomide (CC-4047) for two consecutive days before mAb therapy enhances the antitumor activity of Rituximab and doubled the median survival of lymphoma-bearing mice. Statistically, significant differences are observed between animals treated with Rituximab versus Pomalidomide+Rituximab. The median survival time of animals treated with Pomalidomide and Rituximab is longer (median survival, 74 days; 95% CI, 70-78) than those treated with Rituximab monotherapy (median survival, 38 days; 95% CI, 26-50; log-rank test, P=0.002). The administration of CC-5013 or Pomalidomide for two consecutive days leads to a significant increase in the number of circulating NK cells as shown by flow cytometry analysis, in lymphoma-bearing SCID mice[2]. Following a 50 mg/kg PO administration of Pomalidomide (POM) to rats, unbound concentrations in blood reach a Cmax value of 1100±82 ng/mL at 4.6±2.4 hours, with a concomitant AUC(0-10) value of 6800±2000 ng•hr/mL. Unbound POM in the brain, however, has a Cmax value of 430±63 ng/mL at 4.1±1.5 hours and an AUC(0-10) value of 2700±740 ng•hr/mL, giving an unbound AUCbrain to AUCblood ratio of 0.39±0.03. These values are consistent with excellent blood-brain-barrier penetration. The results obtained in this study are consistent with those seen in a concurrent study looking at whole brain POM content following its oral administration to mice. |
These protocols are for reference only. InvivoChem does not
independently validate these methods.
| Solvent volume to be added | Mass (the weight of a compound) | |||
|---|---|---|---|---|
| Mother liquor concentration | 1mg | 5mg | 10mg | 20mg |
| 1mM | 3.6598 mL | 18.2989 mL | 36.5979 mL | 73.1957 mL |
| 5mM | 0.7320 mL | 3.6598 mL | 7.3196 mL | 14.6391 mL |
| 10mM | 0.3660 mL | 1.8299 mL | 3.6598 mL | 7.3196 mL |
| 20mM | 0.1830 mL | 0.9149 mL | 1.8299 mL | 3.6598 mL |
The molarity calculator equation
Mass(g) = Concentration(mol/L) × Volume(L) × Molecular Weight(g/mol)
Mass
=
Concentration
×
Volume
×
Molecular Weight*
The dilution calculator equation
Concentration(start)
×
Volume(start)
=
Concentration(final)
×
Volume(final)
This equation is commonly abbreviated as: C1 V1 = C2 V2
Concentration(start)
C1
×
Volume(start)
V1
=
Concentration(final)
C2
×
Volume(final)
V2
Step One: Enter information below
Dosage mg/kg
Average weight of animals g
Dosing volume per animal µL
Number of animals
Step Two: Enter the in vivo formulation
%DMSO
+
%
+
%Tween 80
+
%ddH2O
Calculation Results:
Working concentration:
mg/ml;
Method for preparing DMSO master liquid:
mg
drug pre-dissolved in
µL
DMSO(Master liquid concentration
mg/mL)
,Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:
Take
µL
DMSO master liquid, next add
µL
PEG300, mix and clarify, next add
µL
Tween 80,mix and clarify, next add
µL
ddH2O,mix and clarify.
Note:
- (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
- (2) Be sure to add the solvent(s) in order.